Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 3/2004

01-09-2004 | Poster presentation

Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production

Authors: CA Manacu, J Martel-Pelletier, M Roy-Beaudry, J-P Pelletier, JC Fernandes, F Shipkolye, F Moldovan

Published in: Arthritis Research & Therapy | Special Issue 3/2004

Login to get access

Excerpt

Cartilage degradation in osteoarthritis (OA) and rheumatoid arthritis constitutes a major structural change in the joint, which may severely impair its function causing pain and disability. This degradation is accompanied by the release in the synovial fluid of degraded matrix constituents that primarily result from an increased matrix catabolism. Various factors are directly involved in this process. Endothelin-1 (ET-1), a potent vasoconstrictor and promitogen peptide for many cell types, including chondrocytes, was recently identified as one such factor. …
Metadata
Title
Endothelin-1 in osteoarthritic chondrocytes triggers nitric oxide production and upregulates collagenase production
Authors
CA Manacu
J Martel-Pelletier
M Roy-Beaudry
J-P Pelletier
JC Fernandes
F Shipkolye
F Moldovan
Publication date
01-09-2004
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 3/2004
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar1385

Other articles of this Special Issue 3/2004

Arthritis Research & Therapy 3/2004 Go to the issue

Poster presentation

Activation of peroxisome proliferator-activated receptor γ inhibits IL-1β-induced mPGES-1 expression in human synovial fibroblasts by interfering with Egr-1

Poster presentation

Advanced glycation endproducts in the development of osteoarthritis

Poster presentation

P-selectin, an important mediator of angiogenesis in females: the role of estradiol

Poster presentation

The potential role of adiponectin in driving arthritis

Oral presentation

Autoantibodies and cognitive impairment in systemic lupus erythematosus

Poster presentation

Distinct lymphocyte subpopulations in bone marrow from rheumatoid arthritis and osteoarthritis patients: a role for IL-15?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits